MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines
Therapeutic Advances in Vaccines · 2014-05 · 2 (3) · 77-89
DOI: 10.1177/2051013614525375 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Vaccines, online erschienen am 05.03.2014. Verfasst von Joseph D Comber und 1 weiteren Autor:innen. Beteiligte Einrichtung: Immunotope, Inc., Pennsylvania Biotechnology Center, USA. Die Arbeit wurde bisher 127-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Major histocompatibility complex class I (MHC-I) presented peptide epitopes provide a ‘window’ into the changes occurring in a cell. Conventionally, these peptides are generated by proteolysis of endogenously synthesized proteins in the cytosol, loaded onto MHC-I molecules, and presented on the cell surface for surveillance by CD8 + T cells. MHC-I restricted processing and presentation alerts the immune system to any infectious or tumorigenic processes unfolding intracellularly and provides potential targets for a cytotoxic T cell response. Therefore, therapeutic vaccines based on MHC-I presented peptide epitopes could, theoretically, induce CD8 + T cell responses that have tangible clinical impacts on tumor eradication and patient survival. Three major methods have been used to identify MHC-I restricted epitopes for inclusion in peptide-based vaccines for cancer: genetic, motif prediction and, more recently, immunoproteomic analysis. Although the first two methods are capable of identifying T cell stimulatory epitopes, these have significant disadvantages and may not accurately represent epitopes presented by a tumor cell. In contrast, immunoproteomic methods can overcome these disadvantages and identify naturally processed and presented tumor associated epitopes that induce more clinically relevant tumor specific cytotoxic T cell responses. In this review, we discuss the importance of using the naturally presented MHC-I peptide repertoire in formulating peptide vaccines, the recent application of peptide-based vaccines in a variety of cancers, and highlight the pros and cons of the current state of peptide vaccines.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Immunotope, Inc., Pennsylvania Biotechnology Center, USA.
- Immunotope, Inc., Pennsylvania Biotechnology Center, 3805 Old Easton Road, Doylestown, PA 18902, USA.
Zitieren
APA
Comber, J. D., & Philip, R. (2014). MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines. Therapeutic Advances in Vaccines, 2(3), 77-89. https://doi.org/10.1177/2051013614525375
Vancouver
Comber JD, Philip R. MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines. Therapeutic Advances in Vaccines. 2014;2(3):77-89. doi:10.1177/2051013614525375
BibTeX
@article{Comber2014,
author = {Comber, Joseph D and Philip, Ramila},
title = {MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines},
journal = {Therapeutic Advances in Vaccines},
year = {2014},
volume = {2},
number = {3},
pages = {77--89},
doi = {10.1177/2051013614525375}
}
EUVIMED